Synthorx (Synthorx) Cash-to-Debt : 39.16 (As of Sep. 2019)

View and export this data going back to 2018. Start your Free Trial

What is Synthorx Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Synthorx's cash to debt ratio for the quarter that ended in Sep. 2019 was 39.16.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Synthorx could pay off its debt using the cash in hand for the quarter that ended in Sep. 2019.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Synthorx's Cash-to-Debt or its related term are showing as below:

THOR's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.54
* Ranked among companies with meaningful Cash-to-Debt only.

Synthorx Cash-to-Debt Historical Data

The historical data trend for Synthorx's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Synthorx Cash-to-Debt Chart

Synthorx Annual Data

Trend

Dec16

Dec17

Dec18

Cash-to-Debt

No Debt

Synthorx Quarterly Data
	Dec16	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Cash-to-Debt	Get a 7-Day Free Trial				No Debt	No Debt	54.00	51.28	39.16

Competitive Comparison of Synthorx's Cash-to-Debt

For the Biotechnology subindustry, Synthorx's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Synthorx's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synthorx's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Synthorx's Cash-to-Debt falls into.

Synthorx Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Synthorx's Cash to Debt Ratio for the fiscal year that ended in Dec. 2018 is calculated as:

Synthorx had no debt ⁽¹⁾.

Synthorx's Cash to Debt Ratio for the quarter that ended in Sep. 2019 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	150.886	/	(0.502	+	3.351)
	=	39.16

Synthorx (NAS:THOR) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Synthorx Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Synthorx's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Synthorx (Synthorx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synthorx Inc (NAS:THOR) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

11099 North Torrey Pines Road, Suite 290, La Jolla, CA, USA, 92037

Website

http://www.synthorx.com

Executives

Powell Andrew Kenneth William	director	C/O COLLAGENEX PHARMACEUTICALS, INC., 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter A. Thompson	director, 10 percent owner	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Vickie L Capps	director	2985 SCOTT STREET, VISTA CA 92083
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Jay Lichter	director	C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Laura Shawver	director, officer: President and CEO	1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Avalon Ventures X, L.p.	10 percent owner	1134 KLINE STREET, LA JOLLA CA 92037
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vii Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022